-
Media Release
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
-
Media Release
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
-
Media Release
Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
-
Media Release
Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
-
Media Release
Novartis Teams Up With Celebrity Interior Designer Nate Berkus To Launch My Home In Sight, A Program Empowering People With Wet AMD To Live More Independently At Home
-
Media Release
Novartis Teams Up With Celebrity Interior Designer Nate Berkus To Launch My Home In Sight, A Program Empowering People With Wet AMD To Live More Independently At Home
-
Media Release
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
-
Media Release
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
-
Media Release
Novartis Offers Free Genetic Mutation Testing Program for Advanced Melanoma Patients; Results Can Help Doctors and Patients Making Cancer Treatment Decisions
-
Media Release
Novartis Offers Free Genetic Mutation Testing Program for Advanced Melanoma Patients; Results Can Help Doctors and Patients Making Cancer Treatment Decisions
-
Media Release
Long-term Survival Benefit Shown for Metastatic Melanoma Patients Treated with Novartis Tafinlar® + Mekinist®
-
Media Release
Long-term Survival Benefit Shown for Metastatic Melanoma Patients Treated with Novartis Tafinlar® + Mekinist®